Open AccessComparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases
Author(s) -
Laurent Gutmann,
M Kitzis,
Shigeru Yamabe,
Jacqu̧es Acar
Publication year - 1986
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.29.5.955
Subject(s) - carbenicillin , enterobacter cloacae , citrobacter freundii , clavulanic acid , beta lactamase inhibitors , sulbactam , microbiology and biotechnology , ampicillin , antibiotics , beta lactamase , enterobacter , chemistry , biology , citrobacter , enterobacteriaceae , amoxicillin , escherichia coli , biochemistry , antibiotic resistance , imipenem , gene
YTR 830, a new beta-lactamase inhibitor, combined with amoxicillin or carbenicillin, showed a synergistic effect similar to that observed with clavulanic acid, and generally better than that with sulbactam, against strains harboring chromosome-encoded penicillinases and broad-spectrum beta-lactamases or plasmid-determined beta-lactamases. With ampicillin, YTR 830 showed the best synergistic activity of the inhibitors against Proteus morganii, Citrobacter freundii, and Enterobacter cloacae and their mutants with a derepressed chromosome-encoded cephalosporinase.